NEW YORK (GenomeWeb News) – BioFire Diagnostics has appointed Robert Lollini as CFO.

Lollini most recently served as CEO, and formerly as CFO of Myrexis, a Utah-based biotechnology company. He remains a member of its board of directors. From 1993 to 2007, Lollini held multiple executive positions at drug-delivery company Iomed, which was acquired in May 2007. Earlier in his career, he held various executive management positions at RP Scherer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.